Cargando…

Comparing the Value of Data Visualization Methods for Communicating Harms in Clinical Trials

In clinical trials, harms (i.e., adverse events) are often reported by simply counting the number of people who experienced each event. Reporting only frequencies ignores other dimensions of the data that are important for stakeholders, including severity, seriousness, rate (recurrence), timing, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Qureshi, Riaz, Chen, Xiwei, Goerg, Carsten, Mayo-Wilson, Evan, Dickinson, Stephanie, Golzarri-Arroyo, Lilian, Hong, Hwanhee, Phillips, Rachel, Cornelius, Victoria, McAdams DeMarco, Mara, Guallar, Eliseo, Li, Tianjing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780120/
https://www.ncbi.nlm.nih.gov/pubmed/36065832
http://dx.doi.org/10.1093/epirev/mxac005
_version_ 1784856776275918848
author Qureshi, Riaz
Chen, Xiwei
Goerg, Carsten
Mayo-Wilson, Evan
Dickinson, Stephanie
Golzarri-Arroyo, Lilian
Hong, Hwanhee
Phillips, Rachel
Cornelius, Victoria
McAdams DeMarco, Mara
Guallar, Eliseo
Li, Tianjing
author_facet Qureshi, Riaz
Chen, Xiwei
Goerg, Carsten
Mayo-Wilson, Evan
Dickinson, Stephanie
Golzarri-Arroyo, Lilian
Hong, Hwanhee
Phillips, Rachel
Cornelius, Victoria
McAdams DeMarco, Mara
Guallar, Eliseo
Li, Tianjing
author_sort Qureshi, Riaz
collection PubMed
description In clinical trials, harms (i.e., adverse events) are often reported by simply counting the number of people who experienced each event. Reporting only frequencies ignores other dimensions of the data that are important for stakeholders, including severity, seriousness, rate (recurrence), timing, and groups of related harms. Additionally, application of selection criteria to harms prevents most from being reported. Visualization of data could improve communication of multidimensional data. We replicated and compared the characteristics of 6 different approaches for visualizing harms: dot plot, stacked bar chart, volcano plot, heat map, treemap, and tendril plot. We considered binary events using individual participant data from a randomized trial of gabapentin for neuropathic pain. We assessed their value using a heuristic approach and a group of content experts. We produced all figures using R and share the open-source code on GitHub. Most original visualizations propose presenting individual harms (e.g., dizziness, somnolence) alone or alongside higher level (e.g., by body systems) summaries of harms, although they could be applied at either level. Visualizations can present different dimensions of all harms observed in trials. Except for the tendril plot, all other plots do not require individual participant data. The dot plot and volcano plot are favored as visualization approaches to present an overall summary of harms data. Our value assessment found the dot plot and volcano plot were favored by content experts. Using visualizations to report harms could improve communication. Trialists can use our provided code to easily implement these approaches.
format Online
Article
Text
id pubmed-9780120
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-97801202022-12-23 Comparing the Value of Data Visualization Methods for Communicating Harms in Clinical Trials Qureshi, Riaz Chen, Xiwei Goerg, Carsten Mayo-Wilson, Evan Dickinson, Stephanie Golzarri-Arroyo, Lilian Hong, Hwanhee Phillips, Rachel Cornelius, Victoria McAdams DeMarco, Mara Guallar, Eliseo Li, Tianjing Epidemiol Rev Review In clinical trials, harms (i.e., adverse events) are often reported by simply counting the number of people who experienced each event. Reporting only frequencies ignores other dimensions of the data that are important for stakeholders, including severity, seriousness, rate (recurrence), timing, and groups of related harms. Additionally, application of selection criteria to harms prevents most from being reported. Visualization of data could improve communication of multidimensional data. We replicated and compared the characteristics of 6 different approaches for visualizing harms: dot plot, stacked bar chart, volcano plot, heat map, treemap, and tendril plot. We considered binary events using individual participant data from a randomized trial of gabapentin for neuropathic pain. We assessed their value using a heuristic approach and a group of content experts. We produced all figures using R and share the open-source code on GitHub. Most original visualizations propose presenting individual harms (e.g., dizziness, somnolence) alone or alongside higher level (e.g., by body systems) summaries of harms, although they could be applied at either level. Visualizations can present different dimensions of all harms observed in trials. Except for the tendril plot, all other plots do not require individual participant data. The dot plot and volcano plot are favored as visualization approaches to present an overall summary of harms data. Our value assessment found the dot plot and volcano plot were favored by content experts. Using visualizations to report harms could improve communication. Trialists can use our provided code to easily implement these approaches. Oxford University Press 2022-09-18 /pmc/articles/PMC9780120/ /pubmed/36065832 http://dx.doi.org/10.1093/epirev/mxac005 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Review
Qureshi, Riaz
Chen, Xiwei
Goerg, Carsten
Mayo-Wilson, Evan
Dickinson, Stephanie
Golzarri-Arroyo, Lilian
Hong, Hwanhee
Phillips, Rachel
Cornelius, Victoria
McAdams DeMarco, Mara
Guallar, Eliseo
Li, Tianjing
Comparing the Value of Data Visualization Methods for Communicating Harms in Clinical Trials
title Comparing the Value of Data Visualization Methods for Communicating Harms in Clinical Trials
title_full Comparing the Value of Data Visualization Methods for Communicating Harms in Clinical Trials
title_fullStr Comparing the Value of Data Visualization Methods for Communicating Harms in Clinical Trials
title_full_unstemmed Comparing the Value of Data Visualization Methods for Communicating Harms in Clinical Trials
title_short Comparing the Value of Data Visualization Methods for Communicating Harms in Clinical Trials
title_sort comparing the value of data visualization methods for communicating harms in clinical trials
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780120/
https://www.ncbi.nlm.nih.gov/pubmed/36065832
http://dx.doi.org/10.1093/epirev/mxac005
work_keys_str_mv AT qureshiriaz comparingthevalueofdatavisualizationmethodsforcommunicatingharmsinclinicaltrials
AT chenxiwei comparingthevalueofdatavisualizationmethodsforcommunicatingharmsinclinicaltrials
AT goergcarsten comparingthevalueofdatavisualizationmethodsforcommunicatingharmsinclinicaltrials
AT mayowilsonevan comparingthevalueofdatavisualizationmethodsforcommunicatingharmsinclinicaltrials
AT dickinsonstephanie comparingthevalueofdatavisualizationmethodsforcommunicatingharmsinclinicaltrials
AT golzarriarroyolilian comparingthevalueofdatavisualizationmethodsforcommunicatingharmsinclinicaltrials
AT honghwanhee comparingthevalueofdatavisualizationmethodsforcommunicatingharmsinclinicaltrials
AT phillipsrachel comparingthevalueofdatavisualizationmethodsforcommunicatingharmsinclinicaltrials
AT corneliusvictoria comparingthevalueofdatavisualizationmethodsforcommunicatingharmsinclinicaltrials
AT mcadamsdemarcomara comparingthevalueofdatavisualizationmethodsforcommunicatingharmsinclinicaltrials
AT guallareliseo comparingthevalueofdatavisualizationmethodsforcommunicatingharmsinclinicaltrials
AT litianjing comparingthevalueofdatavisualizationmethodsforcommunicatingharmsinclinicaltrials